Depressive Disorder Clinical Trials

478 recruitingLast updated: July 17, 2026

There are 478 actively recruiting depressive disorder clinical trials across 62 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Toronto, Ontario, Canada. Updated daily from ClinicalTrials.gov.


Depressive Disorder Trials at a Glance

478 actively recruiting trials for depressive disorder are listed on ClinicalTrialsFinder across 6 cities in 62 countries. The largest study group is Not Applicable with 249 trials, with the heaviest enrollment activity in New York, Boston, and Toronto. Lead sponsors running depressive disorder studies include Massachusetts General Hospital, Centre for Addiction and Mental Health, and Unity Health Toronto.

Browse depressive disorder trials by phase

Treatments under study

About Depressive Disorder Clinical Trials

Looking for clinical trials for Depressive Disorder? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Depressive Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Depressive Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 478 trials

Recruiting
Phase 2

Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

Major Depressive DisorderAnxiety Disorders
National Institute of Mental Health (NIMH)3,500 enrolled2 locationsNCT00018057
Recruiting
Phase 2

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled23 locationsNCT07284667
Recruiting
Phase 2

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Depression, AnxietySchizophreniaPsychiatric Disorder+5 more
Brigham and Women's Hospital180 enrolled2 locationsNCT06376734
Recruiting
Not Applicable

Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression

Depression - Major Depressive DisorderChildhood Traumas
St. Joseph's Healthcare Hamilton50 enrolled1 locationNCT07250893
Recruiting
Phase 1

Pattern Separation in Major Depressive Disorder

Major Depressive Disorder (MDD)
Jeffrey Miller30 enrolled1 locationNCT07139834
Recruiting
Phase 3

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

Post Traumatic Stress Disorder (PTSD)Major Depressive Disorder
Khyber Medical University Peshawar60 enrolled3 locationsNCT07703722
Recruiting
Not Applicable

Combining rTMS & Aerobic Exercise to Treat Depression and Improve Post-Stroke Walking

StrokeDepression - Major Depressive DisorderWalking Impairment
Medical University of South Carolina96 enrolled2 locationsNCT07050355
Recruiting

An Innovative Master Platform for Clinical Trials in Mood Disorders

Depressive DisorderMood DisordersBipolar and Related Disorders
St. Joseph's Healthcare Hamilton2,200 enrolled9 locationsNCT06408012
Recruiting
Not Applicable

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

DepressionSuicideMajor Depressive Disorder+6 more
University of Alabama at Birmingham240 enrolled2 locationsNCT05437588
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled61 locationsNCT07065240
Recruiting
Phase 2

Inhaled DMT for Major Depressive Disorder

SuicideSuicidal IdeationMajor Depression+2 more
Universidade Federal do Rio Grande do Norte140 enrolled5 locationsNCT07562191
Recruiting
Phase 2

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

DepressionDepressive DisorderMolecular Mechanisms of Pharmacological Action+10 more
National Institute of Mental Health (NIMH)50 enrolled1 locationNCT06511908
Recruiting

Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

Major Depressive Disorder (MDD)
Abraham Nunes252 enrolled9 locationsNCT06746155
Recruiting
Phase 1Phase 2

Cannabidiol Oil for Treatment-Resistant Major Depression

Major Depressive Disorder (MDD)Treatment Resistant Depression (TRD)
Universidade do Sul de Santa Catarina120 enrolled1 locationNCT07696871
Recruiting
Not Applicable

Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression

Major Depressive Disorder (MDD)
University of Oxford60 enrolled1 locationNCT07694076
Recruiting
Not Applicable

EEG Prediction and Clinical Efficacy of tDCS in Major Depression

Depression - Major Depressive Disorder
Ionclinics & Deionic SL270 enrolled1 locationNCT07611773
Recruiting
Phase 3

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Depressive Disorder, Major
Eli Lilly and Company1,000 enrolled180 locationsNCT07412756
Recruiting
Not Applicable

Defining Neurobiological Links Between Substance Use and Mental Illness

Substance Use DisorderNormal PhysiologyMajor Depressive Disorder
National Institute on Drug Abuse (NIDA)620 enrolled1 locationNCT05538910
Recruiting
Phase 3

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled68 locationsNCT05850689
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Depressive Disorder, Major
Janssen Research & Development, LLC258 enrolled30 locationsNCT07227454